M&AHealthcareSIGNED
Fresenius Buys Remaining 45% Stake in mAbxience for €750 Million
Value
€750M
Acquirer
Fresenius
Target
mAbxience (45% stake)
Fresenius has acquired the remaining 45% stake in its biopharmaceutical subsidiary mAbxience for €750 million. This transaction creates an integrated biopharmaceutical platform with capabilities spanning research, development, commercialization, and manufacturing, with a presence in Spain and Latin America.
✦ Meridian Analysis
This full acquisition by Fresenius consolidates its control over mAbxience, aiming to leverage its integrated biopharmaceutical capabilities. The move is strategic for Fresenius as it seeks to enhance its position in the growing biopharmaceutical market, particularly with its established production footprint in key regions.
The Meridian Weekly
The week's largest deals and the Iberian ones, every Monday. Free.